Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Guerci

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Bone Marrow Transplantation|May 1, 1996
The treatment of chronic myelogenous leukemia by interferon and cytosine-arabinoside: rational and design of the French trials. French CML Study GroupF Guilhot, A Guerci, D Fiere, et al.
Leukemia|June 24, 2000
Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemiaX Thomas, H Dombret, C Cordonnier, et al.
Advances in Experimental Medicine and Biology|September 29, 1999
Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMSE Wattel, E Solary, B Hecquet, et al.
British Journal of Haematology|November 7, 2024
Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational studyF Huguet, A Guerci-Bresler, G Roth-Guepin, et al.
British Journal of Haematology|September 12, 1998
Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized studyE Wattel, E Solary, B Hecquet, et al.
The American Journal of Cardiology|April 24, 1999
Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin TherapyJ H Alexander, R A Harrington, R H Tuttle, et al.
Leukemia|April 18, 2002
Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phaseF Maloisel, A Guerci, D Guyotat, et al.
Annals of Hematology|January 30, 2013
High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFMC Kelaidi, O Beyne-Rauzy, T Braun, et al.
British Journal of Haematology|December 21, 2000
Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trialS De Botton, S Chevret, M Sanz, et al.
Leukemia|October 27, 2015
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletionA Toma, O Kosmider, S Chevret, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Bone Marrow Transplantation|May 1, 1996
The treatment of chronic myelogenous leukemia by interferon and cytosine-arabinoside: rational and design of the French trials. French CML Study GroupF Guilhot, A Guerci, D Fiere, et al.
Leukemia|June 24, 2000
Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemiaX Thomas, H Dombret, C Cordonnier, et al.
Advances in Experimental Medicine and Biology|September 29, 1999
Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMSE Wattel, E Solary, B Hecquet, et al.
British Journal of Haematology|November 7, 2024
Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational studyF Huguet, A Guerci-Bresler, G Roth-Guepin, et al.
British Journal of Haematology|September 12, 1998
Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized studyE Wattel, E Solary, B Hecquet, et al.
The American Journal of Cardiology|April 24, 1999
Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin TherapyJ H Alexander, R A Harrington, R H Tuttle, et al.
Leukemia|April 18, 2002
Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phaseF Maloisel, A Guerci, D Guyotat, et al.
Annals of Hematology|January 30, 2013
High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFMC Kelaidi, O Beyne-Rauzy, T Braun, et al.
British Journal of Haematology|December 21, 2000
Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trialS De Botton, S Chevret, M Sanz, et al.
Leukemia|October 27, 2015
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletionA Toma, O Kosmider, S Chevret, et al.
Pageof 8